Reference
Compare peptides
Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.
No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.
Link to this comparison: /compare?peptides=tb-500,bpc-157,thymosin-alpha-1
| TB-500 | BPC-157 | Thymosin alpha-1 | |
|---|---|---|---|
| Identity | |||
| Class | Synthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23) | Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC | Synthetic 28-residue N-acetylated peptide corresponding to the N-terminal fragment of prothymosin alpha |
| Also listed as | Thymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ-OH, TB500 | Pentadecapeptide BPC 157, PL-14736, Bepecin | Thymalfasin, Tα1, Zadaxin |
| Molecular formula | C38H68N10O14 | C62H98N16O22 | C129H215N33O55 |
| Molecular weight | 889.0 g/mol | 1419.5 g/mol | 3108.3 g/mol |
| CAS | 885340-08-9 | 137525-51-0 | 62304-98-7 |
| PubChem CID | 62707662 | 9941957 | 16130571 |
| Sequence length | 7 residues | 15 residues | 28 residues |
| Data caveat | TB-500 is commonly described in vendor material as the Ac-SDKP fragment. Full caveat | None recorded | None recorded |
| United States regulatory status | |||
| Status | No FDA-approved product | No FDA-approved product | No FDA-approved product |
| FDA application | None recorded | None recorded | None recorded |
| Compounding | FDA bulk-substance nomination withdrawn; safety concerns remain published. | FDA bulk-substance nomination withdrawn; safety concerns remain published. | FDA bulk-substance nomination withdrawn; safety concerns remain published. |
| WADA | Named at S2.3 — “Thymosin-β4 and its derivatives e.g. TB-500”. Prohibited at all times; non-Specified. | Named in Class S0 (Non-Approved Substances). Prohibited at all times; Specified Substance. | Not named in this record |
| Evidence on file | |||
| Records | 6 | 9 | 3 |
| Human-interventional records | 0 | 0 | 0 |
| Human-observational records | 0 | 1 | 0 |
| Animal records | 1 | 1 | 0 |
| In-vitro records | 0 | 1 | 0 |
| Reviews | 2 | 3 | 1 |
| Regulatory documents | 3 | 3 | 2 |
| Earliest indexed | 1999 | 2003 | 2016 |
| Latest indexed | 2026 | 2026 | 2026 |
| Records | Open evidence file | Open evidence file | Open evidence file |
Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.